Breaking News

Cantor Fitzgerald analyst Louise Chen noted that the EU's CHMP published its agenda for meetings taking place this week, which includes reference to icosapent ethyl. The meeting timing puts Amarin in-line to "on the earlier side" of potentially receiving a CHMP opinion that it has said would occur in late January to early February of this year, according to Chen, who expects a positive CHMP opinion and for EMA approval to follow within 67 days of a CHMP decision. Chen, who thinks recent updates highlight the "underappreciated opportunities" for Vascepa outside of the U.S., keeps an Overweight rating on Amarin shares with a $10 price target.

Piper Sandler analyst Yasmeen Rahimi reiterates reiterate her "conviction call" on Amarin's potential for European approval of Vascepa, with the Committee for Medicinal Products for Human Use opinion expected in late January or February. Potential European Medicines Agency approval 67 days after the CHMP recommendation is the most important stock-moving catalyst for Amarin shares in 2021, Rahimi tells investors in a research note. She continues to believe Amarin will have a "re-birth" in 202 on Vascepa's continued revenue growth and global market opportunity. The analyst keeps an Overweight rating on the shares with a $19 price target.

KeyBanc analyst Matthew DeGulis raised the firm's price target on Nike (NKE) to $180 from $174 and keeps an Overweight rating on the shares. The analyst notes that data available points to highly discretionary items, like footwear and accessories, taking share following stimulus payments. To the extent that the Biden administration follows through on its incremental $1,400 stimulus payments, which he views as very likely, DeGulis thinks the primary beneficiaries would be Foot Locker (FL), Nike, Tapestry (TPR), and L Brands (LB).